243 related articles for article (PubMed ID: 18518976)
1. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and cost of treatment of genital warts in Spain.
Castellsagué X; Cohet C; Puig-Tintoré LM; Acebes LO; Salinas J; San Martin M; Breitscheidel L; Rémy V
Eur J Public Health; 2009 Jan; 19(1):106-10. PubMed ID: 19112075
[TBL] [Abstract][Full Text] [Related]
3. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France].
Monsonégo J; Breugelmans JG; Bouée S; Lafuma A; Bénard S; Rémy V
Gynecol Obstet Fertil; 2007 Feb; 35(2):107-13. PubMed ID: 17270482
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
6. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Hoy T; Singhal PK; Willey VJ; Insinga RP
Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
8. Determining the cost of genital warts: a study from Ireland.
Dee A; Howell F; O'Connor C; Cremin S; Hunter K
Sex Transm Infect; 2009 Sep; 85(5):402-3. PubMed ID: 19004863
[TBL] [Abstract][Full Text] [Related]
9. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
10. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
11. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
[TBL] [Abstract][Full Text] [Related]
12. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme.
Chow EP; Read TR; Wigan R; Donovan B; Chen MY; Bradshaw CS; Fairley CK
Sex Transm Infect; 2015 May; 91(3):214-9. PubMed ID: 25305210
[TBL] [Abstract][Full Text] [Related]
13. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
14. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.
Woodhall SC; Jit M; Soldan K; Kinghorn G; Gilson R; Nathan M; Ross JD; Lacey CJ;
Sex Transm Infect; 2011 Oct; 87(6):458-63. PubMed ID: 21636616
[TBL] [Abstract][Full Text] [Related]
15. Condylomata acuminata (genital warts): patient demographics and treating physicians.
Fleischer AB; Parrish CA; Glenn R; Feldman SR
Sex Transm Dis; 2001 Nov; 28(11):643-7. PubMed ID: 11677386
[TBL] [Abstract][Full Text] [Related]
16. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
[TBL] [Abstract][Full Text] [Related]
17. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
18. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
19. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Oliphant J; Perkins N
N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
